Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

14 Mar 2020

Abstract excerpt

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in clinical trials. Here, we discuss the potential for extending PARP inhibitor therapies to tumours with deficiencies in the DNA damage-activated protein kinase,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32183301
DOI: 10.3390/cancers12030687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATM-Deficient Cancers Provide New Opportunities for Precision OncologyPMID 32183301Read ↗

Targeting DNA damage repair precision medicine strategies in cancerSemantic proximity Read ↗

Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistanceSemantic proximity Read ↗

The DNA Damaging Revolution: PARP Inhibitors and BeyondSemantic proximity Read ↗

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancerSemantic proximity Read ↗

An update on PARP inhibitors for the treatment of cancerSemantic proximity Read ↗

PARP inhibitors for anticancer therapySemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Development of PARP inhibitors in oncologySemantic proximity Read ↗

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.Semantic proximity Read ↗

PARP inhibitors: A new era of targeted therapy.Semantic proximity Read ↗

Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach.Semantic proximity Read ↗

The potential of PARP inhibitors in genetic breast and ovarian cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.